JAK2 and breast carcinoma: We previously demonstrated that CD44+CD24− cancer cells are enriched in basal-like tumors compared with other breast cancer subtypes [15] and that CD44+CD24− cancer cells have heightened IL-6/JAK2/STAT3 signaling activity compared with other tumor cells [16].